Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 16.68
(0.24%)
CNY 16.68
(0.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.35 Billion CNY | 15.0% |
| 2022 | 1.17 Billion CNY | 65.62% |
| 2021 | 712.21 Million CNY | -19.22% |
| 2020 | 881.67 Million CNY | -10.77% |
| 2019 | 988.08 Million CNY | 15.32% |
| 2018 | 856.81 Million CNY | 17.55% |
| 2017 | 728.89 Million CNY | 6.49% |
| 2016 | 684.46 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 293.39 Million CNY | -16.79% |
| 2024 Q1 | 352.58 Million CNY | 0.18% |
| 2024 Q3 | 310.69 Million CNY | 5.9% |
| 2023 Q4 | 351.95 Million CNY | 6.55% |
| 2023 FY | 1.35 Billion CNY | 15.0% |
| 2023 Q3 | 330.31 Million CNY | 8.49% |
| 2023 Q2 | 304.47 Million CNY | -17.64% |
| 2023 Q1 | 369.7 Million CNY | 13.74% |
| 2022 FY | 1.17 Billion CNY | 65.62% |
| 2022 Q3 | 319.17 Million CNY | 13.84% |
| 2022 Q2 | 280.36 Million CNY | 9.96% |
| 2022 Q1 | 254.96 Million CNY | 6.32% |
| 2022 Q4 | 325.04 Million CNY | 1.84% |
| 2021 Q2 | 155.41 Million CNY | -18.05% |
| 2021 Q1 | 189.64 Million CNY | -7.16% |
| 2021 FY | 712.21 Million CNY | -19.22% |
| 2021 Q4 | 239.81 Million CNY | 88.32% |
| 2021 Q3 | 127.34 Million CNY | -18.06% |
| 2020 FY | 881.67 Million CNY | -10.77% |
| 2020 Q4 | 204.26 Million CNY | 19.69% |
| 2020 Q3 | 170.65 Million CNY | -52.84% |
| 2020 Q2 | 361.88 Million CNY | 149.82% |
| 2020 Q1 | 144.86 Million CNY | -45.06% |
| 2019 Q4 | 263.66 Million CNY | 15.01% |
| 2019 Q3 | 229.26 Million CNY | 0.0% |
| 2019 FY | 988.08 Million CNY | 15.32% |
| 2018 FY | 856.81 Million CNY | 17.55% |
| 2017 FY | 728.89 Million CNY | 6.49% |
| 2016 FY | 684.46 Million CNY | 0.0% |